Gapping up
In reaction to strong earnings/guidance:
- JD +3.5%, NAT +3.1%
M&A news:
- PRNB +9.4% (to be acquired by Sanofi (SNY) for $100 per share in cash); SNY +1.3%
Other news:
- ABEO +13.5% (Abeona Therapeutics and Taysha Gene Therapies entered into license and inventory purchase agreements for ABO-202, an adeno-associated virus (AAV) gene therapy for CLN1 disease)
- PSTI +8.7% (Pluristem Therapeutics and Abu Dhabi Stem Cells Center sign MOU to collaborate in the development of cell therapies and regenerative medicines for the treatment of severe diseases including COVID-19)
- GOLD +7.7% (Berkshire Hathaway reports new position in 13F filing)
- GTHX +7.3% (announces acceptance and priority review of NDA for trilaciclib for patients with small cell lung cancer)
- AXLA +7.2% (announced the publication of results from the company's AXA1665-001 clinical study in Clinical and Translational Gastroenterology)
- PDD +5.2% (to join the NASDAQ-100 Index on August 24)
- DVA +4.1% (commenced a modified "Dutch auction" offer for shares of its common stock for up to $1.0 bln at a price per share of not less than $77.00 and not more than $88.00)
- STOR +3.9% (Berkshire Hathaway reports increased position in 13F filing)
- SU +3.1% (Berkshire Hathaway reports increased position in 13F filing)
- QGEN +2.6% (Paulson & Co reports new position in 13F filing)
- PRSP +2.4% (Jana Partners reports new position in 13F filing)
- NVAX +2.4% (initiates Phase 2b clinical trial for COVID-19 vaccine in South Africa)
- KR +2.1% (Berkshire Hathaway reports increased position in 13F filing)
- NVDA +1.9% (close to deal to acquire Arm by the end of the year, according to Evening Standard)
- TECK +1.7% (Greenlight Capital reports new position in 13F filing)
- LOW +1.6% (Pershing Square reports increased position in 13F filing)
- HD +1.2% (daily foot traffic is 35% higher than the same period of last year, according to WSJ)
- SLQT +1.1% (Soros Fund reports new position in 13F filing)
- DKNG +0.9% (Soros Fund reports new position in 13F filing)
Analyst comments:
- LIFE +6.6% (upgraded to Buy from Neutral at H.C. Wainwright)
- IMRA +4.8% (upgraded to Buy from Neutral at Citigroup)
- INFN +4.6% (upgraded to Buy from Hold at Stifel)
- TDOC +3.4% (upgraded to Outperform from Neutral at Credit Suisse)
- JCOM +2.6% (upgraded to Buy from Neutral at Citigroup)
- EAT +1.9% (upgraded to Buy from Hold at Deutsche Bank)
- ROST +1.3% (upgraded to Outperform from Market Perform at Telsey Advisory Group)
- MGIC +1% (upgraded to Buy from Neutral at H.C. Wainwright)